HomeAI · summaries
Storia in 5 fonti
ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes
With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes, in turn rounding out its oral offering in line with N | With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
- ·
medpagetoday.com
Add-On Orforglipron: Good News for Type 2 Diabetes and Inadequate Glycemic Control
ACHIEVE-5 tested the oral GLP-1 drug in combination with a basal insulin regimen
